medigraphic.com

2016, Number S1

Next >>

Rev Med Inst Mex Seguro Soc 2016; 54 (S1)

Systemic arterial hypertension in México. A consensus to mitigate its comorbidities

Pérez-Rodríguez G

Language: Spanish
References: 14
Page: 3-5
PDF size: 186.58 Kb.


ABSTRACT

Given that systemic arterial hypertension (SAH) is the most common illness presented by the adults who come to primary care in México, in this supplement a group of cardiologists, as well as other specialists, from the Instituto Mexicano del Seguro Social (IMSS) offer a systematic review, a critical analysis, and a national consensus of guidelines as a frame of reference to the daily clinical practice in order to mitigate SAH in México.


REFERENCES

  1. Secretaría de Salud. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2012. Cuernavaca, Morelos, México: Secretaría de Salud; 2012.

  2. Velázquez-Monroy O, Rosas Peralta M, Lara Esqueda A, Pastelín Hernández G, Sánchez-Castillo C, Attie F et al. [Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Final outcomes from the National Health Survey 2000]. Arch Cardiol Mex. 2003;73(1):62-77.

  3. Córdova Villalobos JA. Políticas Públicas en Salud para el Desarrollo de México. Academia Nacional de Medicina. 14 Febrero 2007.

  4. Attie F, Rosas PM. Pasado, Presente y Futuro de la Cardiología. Academia Nacional de Medicina. 2005.

  5. Jatos Group. Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res. 2008;31:2115-27.

  6. Julius S, Nesbitt S, Egan B, Kaciroti NS, Grozinski M, Michelson E; for the TROPHY study group. Trial of Preventing Hypertension. Design and 2-Year Progress Report. Hypertension. 2004;44:146-51.

  7. ALLHAT collaborative research group. Major outcomes in High-risk hypertensive patients randomized to ACE inhibitor or Calcium channel blocker versus diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981-96.

  8. Pharao Study. 29th Annual Meeting. Fukuoka, Japan; 2006.

  9. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical out-comes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25.

  10. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005 Sep 10-16;366(9489):895-906.

  11. Campbell NRC, Tu K, Brant R, Duong-Hua M, McAlister FA. The Impact of the Canadian Hypertension Education Program on Antihypertensive Prescribing Trends for the Canadian Hypertension Education Program Outcomes Research Task Force. Hypertension. 2006;47:22-8.

  12. James PA, Oparil S, Carter BL, Cushman WC, Dennison- Himmelfarb C, Handler J, et al. 2014 guide based on the evidence for the management of Arterial hypertension in adults report of the members of the panel appointed the whole Eighth National Committee (JNC 8) JAMA. 2014;311(5):507-20.

  13. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013,31:1281-357.

  14. NICE clinical guideline 127. Clinical management of primary hypertension in adults. 2011; Disponible en guidance.nice.org.uk/cg127.https:// www.nice.org.uk/guidance/cg127/resources/ guidance-hypertension-pdf




2020     |     www.medigraphic.com